Login / Signup

Quantification of Budesonide Retained in the Sinonasal Cavity After High-Volume Saline Irrigation in Post-Operative Chronic Rhinosinusitis.

Paige A ShipmanBhuvanesh YathavanAmarbir S GillChelsea E PollardVenkata YellepeddiHamidreza GhandehariJeremiah A AltAbigail PulsipherKristine A Smith
Published in: American journal of rhinology & allergy (2024)
The retained dose of budesonide in patients with CRS after HVSI was found to be significantly higher than previously estimated and decreased with time post-ESS. Given that budesonide HVSI is a cornerstone of care in CRS, defining the retained dose and the potential systemic implications is critical to understanding the safety of budesonide HVSI.
Keyphrases
  • chronic rhinosinusitis
  • healthcare
  • palliative care
  • quality improvement
  • risk assessment
  • human health
  • chronic pain
  • drug induced